title: Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.
abstract: BACKGROUND
  The approval of new therapies for metastatic castration-resistant prostate cancer (mCRPC), including the oral agents abiraterone acetate and enzalutamide, has altered the standard of care for patients with mCRPC. Little information exists regarding the sequences in which new therapies for mCRPC with evidence of survival benefits are used.
  
  
  OBJECTIVE
  To describe the sequence of medication use for patients with mCRPC as observed in 3 healthcare data sets.
  
  
  METHODS
  Three healthcare claims data sets were used to identify patients with mCRPC who had no previous use of and were newly initiating 1 of the 2 oral study drugs (ie, abiraterone acetate or enzalutamide). The index date was the first study drug claim after September 1, 2012. Patients were followed until the data cutoff or until being lost to follow-up. Descriptive statistics summarized the proportion of patients receiving 1 line of therapy versus ≥2 lines of therapy. The use of a corticosteroid and the mean monthly pharmacy costs of abiraterone acetate or enzalutamide during the follow-up period were compared between the cohorts.
  
  
  RESULTS
  A total of 3525 patients with mCRPC were identified from data set 1, 499 patients from data set 2, and 1949 patients from data set 3. The first-line use of abiraterone acetate was observed in 74%, 82%, and 80% of data sets 1, 2, and 3, respectively, and the first-line use of enzalutamide was seen in 26%, 18%, and 20%, respectively, of these same populations. The concomitant use of corticosteroids was observed in patients receiving first-line abiraterone acetate and in patients receiving first-line enzalutamide in all 3 data sets. After September 2012, abiraterone acetate was the most frequently administered therapy for mCRPC among the 2 oral agents, abiraterone acetate and enzalutamide. The monthly pharmacy costs associated with abiraterone acetate were significantly lower than those associated with enzalutamide in all 3 data sets.
  
  
  CONCLUSIONS
  Based on the data used in this study, abiraterone acetate was more frequently administered for patients with mCRPC than enzalutamide. The concomitant use of corticosteroids was common in patients receiving first-line abiraterone acetate or first-line enzalutamide therapy. Patients receiving abiraterone acetate had significantly lower monthly pharmacy costs than patients receiving enzalutamide. These findings may facilitate the estimation of the budgetary impact of a treatment mix for population health and for managed care stakeholders.
authors.affiliation: Associate Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, Horsham, PA.
authors.forename: Lorie A
authors.initials: LA
authors.lastname: Ellis
authors.affiliation: Senior Economist, Groupe d'analyse, Ltée, Montréal, Québec, Canada.
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Lafeuille
authors.affiliation: Economist, Groupe d'analyse, Ltée, Montréal, Québec, Canada.
authors.forename: Laurence
authors.initials: L
authors.lastname: Gozalo
authors.affiliation: Economist, Groupe d'analyse, Ltée, Montréal, Québec, Canada.
authors.forename: Dominic
authors.initials: D
authors.lastname: Pilon
authors.affiliation: Vice President, Groupe d'analyse, Ltée, Montréal, Québec, Canada.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lefebvre
authors.affiliation: Senior Director, Health Economics and Outcomes Research, Janssen Scientific Affairs, Horsham, PA.
authors.forename: Scott
authors.initials: S
authors.lastname: McKenzie
keywords: abiraterone acetate; enzalutamide; first-line treatment; metastatic castration-resistant prostate cancer; treatment sequencing